Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.
about
Prospects for vaccine prevention of meningococcal infectionImportance of circulating antibodies in protection against meningococcal diseaseImmunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in UgandaMurine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age.Comparison of counter-current immunoelectrophoresis, latex agglutination, and radioimmunoassay in detection of soluble capsular polysaccharide antigens of Haemophilus influenzae type b and Neisseria meningitidis of groups A or C.Synthetic neoglycoconjugates of cell-surface phosphoglycans of Leishmania as potential anti-parasite carbohydrate vaccinesEvaluation of the safety and immunogenicity in United Kingdom laboratory workers of a combined Haemophilus influenzae type b and meningococcal capsular group C conjugate vaccine.Murine immune response to Neisseria meningitidis group C capsular polysaccharide: analysis of monoclonal antibodies generated in response to a thymus-independent antigen and a thymus-dependent toxoid conjugate vaccineComparative immunogenicity of group 6 pneumococcal type 6A(6) and type 6B(26) capsular polysaccharides.Surface plasmon resonance analysis of antipolysaccharide antibody specificity: responses to meningococcal group C conjugate vaccines and bacteriaPreparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidisRethinking recommendations for use of pneumococcal vaccines in adults.Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay.Peptide mimicry of the meningococcal group C capsular polysaccharidePneumococcal polysaccharides interact with human dendritic cells.Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine.Adverse events temporally associated with meningococcal vaccinesPriming for immunologic memory in adults by meningococcal group C conjugate vaccination.Meningococcal disease: treatment and prevention.Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.Meningococcal conjugate vaccines: optimizing global impact.Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.BCR repertoire sequencing: different patterns of B-cell activation after two Meningococcal vaccines.Vaccine Effectiveness of Polysaccharide Vaccines Against Clinical Meningitis - Niamey, Niger, June 2015.Immunogenicity and safety of a meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with one dose of bivalent and quadrivalent meningococcal polysaccharide vaccines: a phase III, controlled, randomized, andMeningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal VaccinationImmunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine.Development and characterization of an anti-idiotype antibody to the capsular polysaccharide of Neisseria meningitidis serogroup CAntibody response to serogroup A and C meningococcal polysaccharide vaccines in infants born of mothers vaccinated during pregnancyThe impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B StreptococcusTwo enzyme linked immunosorbent assays for detecting antibodies against meningococcal capsular polysaccharides A and C.Virulence, immunity, and vaccine related to Streptococcus pneumoniae.Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.Expanding prevention of invasive meningococcal disease.The epidemiology of meningococcal disease and the impact of vaccines.Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines.
P2860
Q24537338-E5777023-E5C3-4A73-99C7-D0911ACC5CB6Q27023516-6A73826C-C7F3-4AFA-9EF2-370B63B441AFQ33388680-056C17F7-8980-45E0-B537-D5F3A7608D2AQ33767903-A6281964-B055-4852-8D78-2BD75C379F7EQ33769150-E559F623-FFA2-4E03-AE71-FE75C491D5ECQ33846773-5EF3BD91-B074-43B4-A24E-C6269E20F1DEQ33870163-018F1D00-4472-4F62-BBE3-01A480C17E89Q33959308-9677E88E-1022-41F6-952B-34AF43AB26D8Q34003052-4490571E-5C3C-4048-A0F1-E2780F3596D9Q34101106-83FED5A1-8F2C-4E9D-85A5-492E6514E3E5Q34145007-B5414CB3-E4FF-42DA-AF5A-26428845335EQ34260060-86067B0F-2B8D-48FB-B0B2-8DD24FCEB823Q34326459-11DB30C1-9E3A-4D99-A472-F61CAD7A7DD5Q34333219-EB99F0D1-964D-4BFD-9C3B-EE53E9074F30Q34404304-3DF06C5A-C1EB-48DE-9F27-6AE613718913Q34491760-8B73F243-7439-4F83-8505-E688A31C9515Q34531872-B0A63E28-5C1B-4D36-B38D-67EAD1AFFF3FQ34711540-4F83E883-7805-4E4C-8E25-61C6FA291FD1Q34720293-EA39E382-99BC-4CBE-9CD5-4584498631DBQ35055030-02691A34-4576-4346-BCE0-2ED2B6A296CEQ35273041-F27BD37C-8CA7-4CFE-AFAC-A1BD7DEE283BQ35547767-2294A19C-2C8C-49B9-BA97-5603B43ED2F0Q35887288-A377E534-72C7-4ABC-BE77-7BD8F84EE37DQ36001047-028A2302-8DF3-403B-8EC5-4554B4CD146DQ36011900-9C84263E-B066-4559-8FB0-2F0C0212119BQ36086273-F7A5A1EC-EEAE-4D4B-B09F-ED7EF6108D95Q36154043-72996781-6317-46EC-B4DF-6FE74942E572Q36228084-2C62AFD7-0679-4E87-859B-3650B11AB3A4Q36265012-022D9D19-2738-4211-AA4E-151185CE7C7EQ36874953-965740D9-A7C5-4D9A-B986-B6F7FAEC5B27Q37003930-53831E02-1DF1-4C8D-9C6B-6C8160E0AAACQ37022545-705771AB-8624-47F7-8A0B-8EC6E4592956Q37037419-C715A5E9-3B35-4E3E-B62B-96463E199D01Q37044249-487EF500-001D-4F5F-97E8-2FF483415BFDQ37250514-4BDD78B3-FA02-4CCE-93EF-FFAFD218374FQ37420816-605D5F9C-8EC4-4887-9BBA-9B92C2BDC403Q37461347-835C8706-826A-4F22-B547-F6F09729D725Q37503239-CD4205CC-F5B0-4880-81B6-4D8AC5F812FEQ37706585-E576EB3D-51F9-4574-9D67-9FD959A02C37Q37857246-947CE9D1-3571-4939-A47B-D305E9A24DE2
P2860
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.
description
1975 nî lūn-bûn
@nan
1975年の論文
@ja
1975年論文
@yue
1975年論文
@zh-hant
1975年論文
@zh-hk
1975年論文
@zh-mo
1975年論文
@zh-tw
1975年论文
@wuu
1975年论文
@zh
1975年论文
@zh-cn
name
Clinical evaluation of group A ...... accharide vaccines in infants.
@ast
Clinical evaluation of group A ...... accharide vaccines in infants.
@en
type
label
Clinical evaluation of group A ...... accharide vaccines in infants.
@ast
Clinical evaluation of group A ...... accharide vaccines in infants.
@en
prefLabel
Clinical evaluation of group A ...... accharide vaccines in infants.
@ast
Clinical evaluation of group A ...... accharide vaccines in infants.
@en
P2093
P2860
P356
P1476
Clinical evaluation of group A ...... accharide vaccines in infants.
@en
P2093
Goldschneider I
Gotschlich EC
P2860
P304
P356
10.1172/JCI108235
P407
P577
1975-12-01T00:00:00Z